The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression

Amanda Mocroft, Wendy P Bannister, Ole Kirk, Justyna Dominika Kowalska, Peter Reiss, Antonella D'Arminio-Monforte, Jose Gatell, Martin Fisher, Hanna Trocha, Aza Rakhmanova, Jens D Lundgren, the EuroSIDA Study in EuroCOORD

    8 Citationer (Scopus)

    Abstract

    BACKGROUND: The aim of this study was to determine whether there is a protective effect of combination antiretroviral therapy (cART) on the development of clinical events in patients with ongoing severe immunosuppression. METHODS: A total of 3,780 patients from the EuroSIDA study under follow-up after 2001 with a current CD4(+) T-cell count ≤200 cells/mm(3) were stratified into five groups: group 1, viral load (VL)100,000 copies/ml (IRR 0.66; 95% CI 0.44-1.00). Similar relationships were seen for non-AIDS events and AIDS events when considered separately. CONCLUSIONS: In patients with ongoing severe immunosuppression, cART was associated with significant clinical benefits in patients with suboptimal virological control or virological failure.
    OriginalsprogEngelsk
    TidsskriftAntiviral Therapy
    Vol/bind17
    Udgave nummer7
    Sider (fra-til)1291-1300
    ISSN1359-6535
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression'. Sammen danner de et unikt fingeraftryk.

    Citationsformater